TY - JOUR
T1 - Fever after immunization
T2 - Current concepts and improved future scientific understanding
AU - Kohl, Katrin S.
AU - Marcy, S. Michael
AU - Blum, Michael
AU - Jones, Marcy Connell
AU - Dagan, Ron
AU - Hansen, John
AU - Nalin, David
AU - Rothstein, Edward
N1 - Funding Information:
Financial support. The review was conducted as part of the Brighton Collaboration, which receives its funding from the Centers for Disease Control and Prevention, the World Health Organization, and the European Research Grant for Improved Vaccine Safety Surveillance.
PY - 2004/8/1
Y1 - 2004/8/1
N2 - Fever is a common clinical complaint in adults and children with a variety of infectious illnesses, as well as a frequently reported adverse event following immunization. Although the level of measured temperature indicative of a "fever" was first defined in 1868, it remains unclear what role fever has as a physiologic reaction to invading substances, how best to measure body temperature and compare measurements from different body sites, and, consequently, how to interpret fever data derived from vaccine safety trials or immunization safety surveillance. However, even with many aspects of the societal, medical, economic, and epidemiologic meanings of fever as an adverse event following immunization (AEFI) still elusive, it is a generally benign - albeit common - clinical sign. By standardizing the definition and means of assessment of fever in vaccine safety studies, thereby permitting comparability of data, we hope to arrive at an improved understanding of its importance as an AEFI.
AB - Fever is a common clinical complaint in adults and children with a variety of infectious illnesses, as well as a frequently reported adverse event following immunization. Although the level of measured temperature indicative of a "fever" was first defined in 1868, it remains unclear what role fever has as a physiologic reaction to invading substances, how best to measure body temperature and compare measurements from different body sites, and, consequently, how to interpret fever data derived from vaccine safety trials or immunization safety surveillance. However, even with many aspects of the societal, medical, economic, and epidemiologic meanings of fever as an adverse event following immunization (AEFI) still elusive, it is a generally benign - albeit common - clinical sign. By standardizing the definition and means of assessment of fever in vaccine safety studies, thereby permitting comparability of data, we hope to arrive at an improved understanding of its importance as an AEFI.
UR - http://www.scopus.com/inward/record.url?scp=3943107534&partnerID=8YFLogxK
U2 - 10.1086/422454
DO - 10.1086/422454
M3 - Review article
C2 - 15307007
AN - SCOPUS:3943107534
VL - 39
SP - 389
EP - 394
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 3
ER -
